Table 2. Patient informative for therapy-naïve and CRPC tumors assessed by ROS assay:

Therapy-naïve and CRPC PCa patient tissue information, including tissue type, therapy, gleason score (GS), tumor source, and metastatic site for tumors assessed by ROS assay. Therapies include radiation (RT), androgen deprivation therapy (ADT), AR-targeted therapies: bicalutamide (Bic), enzalutamide (Enz), abiraterone (Abi), chemotherapy: cabitaxel (Cab), unspecified chemotherapy (Chemo).

Patient Number	Tissue Type	Therapy	GS	Tumor Source	Metastatic Site
1	Therapy-naïve	Naïve	7	Prostate	N/A
2	Therapy-naïve	Naïve	8	Prostate	N/A
3	Therapy-naïve	Naïve	9	Prostate	N/A
4	Therapy-naïve	Naïve	8	Prostate	N/A
5	Therapy-naïve	Naïve	7	Prostate	N/A
6	Therapy-naïve	Naïve	9	Prostate	N/A
1	CRPC	ADT, Abi, Enz, Caba	10	Prostate	Bone (widespread metastasis)
2	CRPC	ADT, Abi, Chemo	N/A	Prostate	N/A
3	CRPC	RT, ADT	8	Prostate	N/A
4	CRPC	ADT, Bic	8	Prostate	N/A
5	CRPC	N/A	10	Prostate	N/A